| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 26.72 | 603 |
| Intrinsic value (DCF) | 1.31 | -66 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
ABIONYX Pharma SA (ABNX.PA) is a French biotechnology company specializing in the discovery and development of innovative therapies for renal and ophthalmological diseases. Headquartered in Balma, France, and listed on Euronext Paris, the company focuses on leveraging its proprietary bio-HDL (high-density lipoprotein) technology to address unmet medical needs in cardiovascular and metabolic diseases. ABIONYX's pipeline includes CER-001, a pre-beta HDL mimetic for post-acute coronary syndrome and familial hypoalphalipoproteinemia; CER-002, a PPARδ agonist targeting cardiovascular and metabolic disorders; and CER-209, a candidate for liver metabolic diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). The company collaborates with GTP Biologics and VBI Therapeutics for bioproduction, enhancing its R&D capabilities. Formerly known as Cerenis Therapeutics, ABIONYX rebranded in 2019 to reflect its refined focus on HDL-based therapeutics. With a market cap of approximately €44.5 million, the company operates in the competitive biotech sector, aiming to commercialize breakthrough treatments for chronic and rare diseases.
ABIONYX Pharma presents a high-risk, high-reward investment opportunity due to its niche focus on HDL-based therapies and early-stage pipeline. The company's €4.6 million revenue (FY 2024) is overshadowed by a net loss of €4.4 million, reflecting the capital-intensive nature of biotech R&D. While its €3.2 million cash reserves and manageable €2.8 million debt provide short-term runway, the lack of profitability (EPS of -€0.14) and negative operating cash flow (-€3.6 million) underscore dependency on funding milestones. The 1.024 beta suggests market-aligned volatility, typical for clinical-stage biotechs. Investors should monitor CER-001's clinical progress and partnerships, as success could position ABIONYX as a leader in HDL therapeutics. However, competition in metabolic disease space and regulatory hurdles pose significant risks.
ABIONYX Pharma competes in the crowded HDL and metabolic disease therapeutics market, differentiating itself through its bio-HDL platform. Its CER-001 candidate targets rare lipid disorders, a niche with limited alternatives, but faces competition from approved HDL-modifying drugs like Amarin's Vascepa (omega-3 fatty acids) and Esperion's bempedoic acid. CER-002's PPARδ agonist mechanism competes with Eli Lilly's tirzepatide (GLP-1/GIP receptor agonist) and Novo Nordisk's semaglutide, though ABIONYX's approach focuses on HDL functionality rather than glycemic control. The company's asset-light model via partnerships (e.g., GTP Biologics) reduces infrastructure costs but limits control over production. ABIONYX's small size (~€44.5M market cap) restricts commercialization capabilities compared to larger peers, necessitating licensing deals. Its French base offers EU regulatory advantages but may complicate U.S. market access. The primary competitive edge lies in CER-001's unique HDL-mimetic action, but clinical validation is critical to outpace rivals in cardiovascular and metabolic niches.